Inovio spinout plans pivotal study for cancer vaccine as it touts alternative take on PhIb/IIa liver cancer data

Paul Schloesser

Associate Editor

Inovio spinout Geneos Therapeutics said Tuesday that it has three new partial responses and one case of stable disease from a mid-stage liver cancer trial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Inovio spinout plans pivotal study for cancer vaccine as it touts alternative take on PhIb/IIa liver cancer data

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA says Ozempic, Wegovy shortage is over

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Merck KGaA tees up changes to leadership team; Ex-CVS Health CEO joins Thermo Fisher’s board

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

In­ovio spin­out plans piv­otal study for can­cer vac­cine as it touts al­ter­na­tive take on PhIb/IIa liv­er can­cer da­ta

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Inovio spinout plans pivotal study for cancer vaccine as it touts alternative take on PhIb/IIa liver cancer data